secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000950170-25-029021
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q4 revenue up 27% to $126.7M; net income $7.7M vs loss year ago; guides FY25 rev $480-535M
--------------------------------------------------------------------------------

- Q4 net revenue $126.7M (+27%); Advanced Wound Care $118.6M (+27%), Surgical/Sports $8.1M (+24%).
- Q4 net income $7.7M ($0.05 diluted EPS) vs net loss $0.6M; adjusted net income $8.8M vs $1.9M.
- FY24 revenue $482.0M (+11%); net income $0.9M vs $4.9M; adjusted net income $20.5M vs $12.7M.
- Cash $136.2M, zero debt (vs $104.3M cash and $66.2M net debt year-end 2023).
- FY25 guidance: revenue $480-535M; net income $9.5-38.8M; Adj. EBITDA $43.6-83.2M; ReNu BLA submission targeted by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000095017025029021/0000950170-25-029021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000095017025029021/orgo-20250227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-029021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer